Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Withdrawn 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Gastrointestinal 3Dermatologic 3Gynecologic 2Sarcoma 1Head & Neck 1

Conditions

Melanoma 2Skin Neoplasms 1Melanoma, Cutaneous Malignant 1

Interventions

Nivolumab 168Ipilimumab 152pembrolizumab 143Cyclophosphamide 126Interleukin-2 70aldesleukin 69fludarabine phosphate 68Radiotherapy 67Biopsy 53Temozolomide 48Blood Specimen Collection 45Peripheral Blood Stem Cell Transplantation 44fludarabine 43Radiosurgery 40trametinib 38Vemurafenib 36dabrafenib 33sargramostim 32Bevacizumab 31Aminolevulinic Acid 31Magnetic Resonance Spectroscopy 30Mycophenolic Acid 29Specimen Handling 28Whole-Body Irradiation 27Photochemotherapy 26Imiquimod 26CTLA-4 Antigen 26Busulfan 26Tacrolimus 25Surveys and Questionnaires 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Electrochemotherapy × Dermatologic × Clear all
NCT06388252 2026-02-19

Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients

Institute of Oncology Ljubljana

Phase NA Enrolling by invitation
10 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT07404605 2026-02-19

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Institute of Oncology Ljubljana

Phase NA Recruiting
150 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡